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RapamycinWepreviously reported activation of the unfolded protein response (UPR) in P23H rhodopsin (RHO) retinaswith
autosomal dominant retinitis pigmentosa (ADRP). Knowing that theUPR can trigger Ca2+ release from the endo-
plasmic reticulum and regulate cellular signaling we examined the level of Ca2+-regulated proteins. We also
looked for changes in the expression of Bcl2 family proteins, autophagy proteins and the mTOR/AKT pathways,
aswell as for the induction ofmitochondria-associated apoptosis in the P23H RHO retina. Our data demonstrated
that the elevation of calpain and caspase-12 activitywas concomitantly observedwith a decrease in the BCL2-XL/
BAX ratio and an increase in mTor levels in the P23H-3 RHO retina suggesting a vulnerability of P23H RHO pho-
toreceptors to apoptosis. The translocation of BAX to themitochondria, aswell as the release of cytochrome C and
AIF into the cytosol supports this conclusion and indicates the involvement ofmitochondria-induced apoptosis in
the progression of ADRP. The level of autophagy proteins in general was found to be decreased in the P21–P30
P23H RHO retina. Injections of rapamycin, however, protected the P23H RHO rod photoreceptors from
experiencing physiological decline. Despite this fact, the downregulation of mTOR did not alter the level of
autophagy proteins. Our results imply that in addition to activation of the UPR during ADRP progression, photo-
receptors also experience alterations in major proapoptotic pathways.
© 2014 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
Retinitis pigmentosa (RP) is a heterogeneous group of eye disorders
that result in irreversible blindness. Visual symptoms include night
blindness, followed by photopia and decreasing visual ﬁelds, leading
to tunnel vision and eventually legal blindness [1,2]. Most frequent-
ly autosomal dominant RP (ADRP) is associated with mutations in
rhodopsin (RHO), with such mutations accounting for approximate-
ly 25% of all ADRP cases [1]. Based on their biochemical and cellular
properties, ADRP rhodopsin mutations have been classiﬁed into six
groups, however most fall into the class I or class II categories [3].
Class I mutations can fold normally, but are not correctly transported
to the outer segment. The S334ter RHO protein expressed in transgenic
rats represents a Class I mutation. The substitution of proline for his-
tidine at position 23 within the rhodopsin (P23H RHO) gene yields
a Class II mutation. These RHO mutants are defective for proper
folding. They are retained in the endoplasmic reticulum (ER) anderms of the Creative Commons
tribution, and reproduction in
credited.
nces, University of Alabama at
33, United States. Tel.: +1 2 5
lished by Elsevier Inc. All rights reserare unable to form a functional chromophore with 11-cis-retinal.
They are then transported to the cytoplasm for degradation by the
proteasome [4].
In 1990 the P23H RHO mutant was proposed to cause ADRP [5].
Since then, the expression of P23Hmutant rhodopsin (RHO) in photore-
ceptors has been studied in transgenic mice [6–8], rats [9–11] and frogs
[12–14]. Loss of photoreceptors and the course of visual decline have
been previously described for rats expressing both the S334ter and
P23H RHO transgenes (http://www.ucsfeye.net/mlavailRDratmodels.
shtml) [15,16]. However, molecular mechanism involved in the loss
of vision in Class I and II mutations has not been studied in detail.
Previously, we have demonstrated that activation of the unfolded
protein response (UPR) occurs during retinal degeneration in both
the S334ter and P23H RHO rat models [11,17,18]. In the S334ter
transgenic retina we have also determined that activation of the
UPR is associated with increased expression of the JNK, Bik, Bim,
Bid, Noxa, and Puma genes and cleavage of caspase-12 that, together
with activated calpains, presumably compromise the integrity of the
mitochondrial MPTP in ADRP photoreceptors [18]. In P23H-3 RHO
rats there have been no cellular signaling pathways identiﬁed as being
involved in the mechanism underlying photoreceptor degeneration
with the exception of the UPR [11,17,19]. Therefore, there is a critical
need to describe any pathways that are modiﬁed concomitantly with
the activated UPR in P23H-3 RHO photoreceptors in order to validate
new therapeutic targets.ved.
666 O.S. Sizova et al. / Cellular Signalling 26 (2014) 665–672The UPR is initiated by the activation of three signaling pathways
(PERK, ATF6 and IRE1) and is required for controlling ER protein folding
capacity and reestablishing homeostasis in the cell. Upon acute or unre-
solved ER stress, the UPR also triggers apoptosis, which eliminates any
cell that is incapable of restoring proper protein folding and orchestrat-
ing a coordinated adaptive downstream response. Previously, we dem-
onstrated that P23H-3 RHO photoreceptors have an activated ER stress-
induced caspase-7 [17] and a consistent increase in Bip and CHOP gene
expression [11]. These results suggested that ER stress persists in P23H-
3 RHO photoreceptors, which might stimulate apoptotic signaling in
these animals. Subsequently the persistence of the UPR has been con-
ﬁrmed in our other study [11]. However, apart from the UPR, other sig-
naling pathways have been found to originate from the ER and those
pathways have not been properly investigated. For example, the
Ca2+-mediated signaling pathway could be triggered by the ER stress
response leading to activation of calpains and caspase-12 [20,21]. The
Bcl2 family proteins are known to be upregulated during UPR activation
via the transcriptional activity of ATF4 and CHOP (Puma, Noxa and Bim).
They can also be upregulated by activated JNK, which phosphorylates
the BCL-2/BCL-XL proteins and additionally, promotes autophagosome
formation by releasing the active beclin-1/PI3K complex from the ER.
This complex is known to regulate ATG12–ATG5 formation and to pro-
mote the LC3-II conversion during the formation of autophagosomes
[22]. Therefore, autophagy, the major degradation pathway after UPR
activation in neuronal cells, could also be induced by ER stress. Both
the PERK/eIF2α and IRE1 arms of the UPR have been implicated in the
regulation of autophagy [23].
mTOR/AKT signaling is another example of a pathway that is tightly
regulated by the UPR. We have previously reported that a T17M RHO
retina that experiences UPR activation also demonstrates an elevation
of mTor protein and a decrease in phosphorylated AKT [21]. It has
been demonstrated that the UPR can activate mTOR via ATF6a signaling
[24]. The ATF6 UPR pathway was found to be upregulated in both P23H
and T17MRHO retinas [17,21], thus implying that similar to T17M RHO,
P23HRHOphotoreceptors could also havemodiﬁedmTOR/AKT signaling.
Thus, several signaling pathways have been identiﬁed that aremedi-
ated by the activation of the UPR, which is found in P23H-3 RHO photo-
receptors [11,17,19]. They could be modiﬁed either by ER stress or
independently altered to contribute to the mechanism of ADRP. In
both scenarios, these signaling pathways could provide alternative ther-
apeutic strategies in the P23H RHO retina in addition to gene therapy
against mutant rhodopsin. Therefore, the major focus of this study is
to identify whether UPR activation in P23H RHO photoreceptors is ac-
companied by changes in Ca2+-induced signaling, autophagy, and
mTOR/AKT pathways during ADRP progression andwhether alterations
in mTOR cellular signaling could be responsible for slowing the rate of
retinal degeneration.
2. Materials and methods
2.1. Animal use
All animal procedures conformed to the Association for Research in
Vision andOphthalmology Statement for theUse of Animals inOphthal-
mic andVision Research, andwere approved by the Institutional Animal
Research Committee of the University of Alabama at Birmingham. The
P23H-3 RHO (line 3) rats were kindly provided by Dr. LaVail (UCSF).
Rats were housed in speciﬁc pathogen-free (SPF) conditions with a
12-hour light and 12-hour dark cycle. Animals were sacriﬁced by thora-
cotomy, and retinas were rapidly excised (removal of the lens), placed
on an ice-cold plate, and stored at−80 °C.
2.2. RNA preparation and quantitative real-time PCR
Total RNAwas isolated from individual SD and P23H-3 RHO (N = 4)
retinas using an RNeasy Mini kit (Qiagen, Valencia, CA).We then used ahigh capacity cDNA reverse transcription kit (Applied Biosystems, Carls-
bad, California, USA). Two cDNA reactions were prepared from each
RNA sample and 10 ng cDNA was used for qRT-PCR using Applied
Biosystems TaqMan assays that were validated for each selected gene
on a One Step Plus instrument (Applied Biosystems, Foster City, CA).
To analyze the samples, we compared the number of cycles (Ct) needed
to reach the midpoint of the linear phase and normalized all observa-
tions to the GAPDH housekeeping gene. The replicated RQ (Relative
Quantity) values for each biological sample were averaged.
2.3. Retinal protein extract for western blot analysis
We obtained retinal protein extracts from dissected retinas that
were sonicated in a buffer containing 25 mM sucrose, 100 mM
Tris–HCl, pH = 7.8, and a mixture of protease inhibitors (PMSF,
TLCK, aprotinin, leupeptin, and pepstatin). The total protein concen-
tration from individual retinas was measured using a Bio-Rad pro-
tein assay, and 40 μg of total protein was used to detect individual
proteins. The detection of proteins was performed using an infrared
secondary antibody and an Odyssey infrared imager (Li-Cor, Inc.).
Antibodies against PUMA (7467S), ATG5 (8540P), ATG7 (78558P),
LC3 (#2775), mTOR (2983P), caspase-3 (9662P), caspase-9 (9507S) and
caspase7 (9492P)were purchased from Cell Signaling (1:1000). Antibod-
ies against AIF (sc5586), Cytochrome C (sc13156), NOXA (sc11718),
and active BAX, which detects only the active form of the BAX pro-
tein (sc23959) were purchased from Santa-Cruz Biotechnology
(1:1000). Anti-caspase-12 (ab62484) and anti-pAKT (ab66138),
which detects phosphorylated AKT, were purchased from Abcam
(1:1000). We used an anti-BAX antibody (B8429) and an anti-
Lamp2 (L0668) antibody from Sigma-Aldrich (1:1000). β-Actin was
used as an internal control and was detected using an anti-β-actin
antibody (Sigma-Aldrich).
2.4. Intraperitoneal injection of rapamycin and ERG analysis
A 10 mg/kg dose of rapamycinwas used for injections. Awater solu-
tion of 5% ethanol, 5% tween-20 and 5% polyethylene glycol 400 was
used to dissolve rapamycin and was also used in the vehicle-treated
control injections. Starting at P15, daily intraperitoneal injections (IPs)
were performed in rats over the course of 10 days, during which no
signs of weight loss were recorded. The ElectroRetinoGrams (ERG) of
treated and untreated animals were recorded as previously described
[25] at P30 and P45, which correlate with 2 and 4 weeks post-
treatment, respectively. Brieﬂy, rats were dark-adapted overnight, then
anesthetized with ketamine (100 mg/kg) and xylazine (10 mg/kg).
Their pupilswere dilated in dim red lightwith 2.5%phenylephrine hydro-
chloride ophthalmic solution (Akorn, Inc.). The KC UTAS-3000 Diagnostic
System (Gaithersburg, MD) was used to perform scotopic ERGs. The
measurements were conducted using a wire contacting the corneal
surface with 2.5% hypromellose ophthalmic demulcent solution
(Akorn, Inc.). The ERG was performed at different intensities includ-
ing 0 dB (2.5 cd*s/m2), 5 dB (7.91 cd*s/m2), 10 dB (25 cd*s/m2),
and 15 dB (79.1 cd*s/m2).
2.5. Calpain activity assay
The detection of calpain activity was performed using the Calpain
Activity Assay kit from BioVision in accordancewith themanufacturer's
recommendations. The detection of the cleaved substrate Ac-LLY-AFC
was performed using a ﬂuorometer that was equipped with a 400-nm
excitation ﬁlter and 505-nm emission ﬁlter.
2.6. Isolation of mitochondria from rat retinas
We separated the cytosolic fraction from themitochondrial fractions
from ﬁve individual P23H RHO and SD rats using the Mitochondria
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arated from the cytoplasm using the Dounce stroke method as recom-
mended by the manufacturer. The protein concentration for each
fraction was determined using a Bio-Rad protein assay. To conﬁrm the
absence of mitochondrial contamination in the cytoplasmic fractions,
western blot was done using a COXIV antibody (Abcam). To conﬁrm
the absence of cytosolic contamination in the mitochondrial fractions,
western blotting with an anti-actin antibody was employed (Sigma-
Aldrich).3. Results
We previously described the activation of the ER stress response in
P23H-3 RHO rat retinas at P30 [17]. For this reason, the modulation of
the other cellular signaling pathways in the P23H RHO photoreceptor
was primarily studied at P30 and P40.
3.1. The hallmarks of Ca2+-induced signaling are upregulated in
deteriorating P23H-3 RHO photoreceptors
We investigated the expression of Calpain 1 and 2, as well as
Caspase-12, and found no differences in calpain 1 or 2 mRNA compared
with controls. However, we did observe signiﬁcant differences in
the caspase-12 gene expression at P21, P30 and P40 (Fig. 1A). At
each time point, caspase-12 mRNA was induced by more than 2-fold
compared to SD. At P21, the relative caspase-12 expression was
3.67 ± 1.03 in P23H RHO vs. 1.60 ± 0.49 in arbitrary units (a.u.)
in SD, P b 0.05. At P30 it was 3.76 ± 0.18 in P23H RHO vs.
1.38 ± 0.19 a.u. in SD, P b 0.05 and at P40 it was 2.36 ± 0.17 in
P23H RHO vs. 1.04 ± 0.09 a.u. in SD, P b 0.05.
An analysis of activated calpain 1 and 2 demonstrated that at P30,
the activation of calpainswas 30% higher in P23H RHO retinas compared
to SD (0.45 ± 0.02 in P23H RHO photoreceptors vs. 0.34 ± 0.02 in SD
a.u., P = 0.01) (Fig. 1B). Cleavage of caspase-12 in P23H RHO retinas
was 2.6-fold higher compared to SD (0.36 ± 0.06 in P23H photorecep-
tors vs. 0.14 ± 0.03 in SD a.u., P = 0.02) (Fig. 1C).
3.2. The expression of Bcl-2 family proteins is modulated in P23H-3
RHO retina
We analyzed Bcl-2 family protein expression by western blot analy-
sis (Fig. 2) and found that the level of anti-apoptotic BCL2-XL protein
was decreased in transgenic retinas by 0.6-fold (0.15 ± 0.02 in P23H
RHO photoreceptors vs. 0.24 ± 0.003 in SD a.u.) at P30 and by 0.4-fold
(0.095 ± 0.01 in P23H RHO photoreceptors vs. 0.23 ± 0.07 in SD a.u.,
P b 0.05) at P40. Alternatively, the expression of proapoptotic BH3-
only proteins, such as BAX and PUMA, increased over time. The level
of BAX was dramatically increased (136-fold) at P30 (0.68 ± 0.18 in
P23H photoreceptors vs. 0.005 ± 0.002 in SD a.u., P b 0.0001). At P40,
BAX protein levels were signiﬁcantly decreased (0.003 ± 0.0002 in
P23H RHO photoreceptors vs. 0.002 ± 0.0002 in SD a.u.). PUMA protein
was not statistically different compared to SD at P30 (0.059 ± 0.01 in
P23H RHO photoreceptors vs. 0.060 ± 0.005 in SD a.u.), but at P40, its
expression was signiﬁcantly elevated by 1.7-fold (0.09 ± 0.004 in
P23H photoreceptors vs. 0.05 ± 0.006 in SD a.u., P b 0.01). The level
of NOXA protein decreased over time. However, this decrease was not
statistically signiﬁcant compared to SD at P30 (0.004 ± 0.0004 in
P23H RHO photoreceptors vs. 0.005 ± 0.0007 in SD a.u.). At P40, the
level of Noxa was reduced by 40% (0.003 ± 0.0002 in P23H photore-
ceptors vs. 0.005 ± 0.0007 in SD a.u., P b 0.05).Fig. 1. The activation of calpains, ER stress-induced caspase-12 andapoptotic protease activat-
ing factor-1-mediated caspase-9. (A) Relative caspase-12 gene expression in progressive
P23H RHO retina. We analyzed caspase-12 gene expression by two-way ANOVA and found
that at P21, P30 and P40 there was a greater-than 2-fold overexpression of caspase-12
mRNA in transgenic retinas (P b 0.05), N = 4. (B) We used the calpain μ and m activity
assay, analyzed the results by a non-parametric t-test and found that the amount of the
cleaved calpain substrate, Ac-LLY-AFC, was increased by 32% in transgenic retinas, N = 4.
(C) The amount of cleaved caspase-12was also elevatedby157% inP23HRHO retinas. (D) Im-
ages of western blots probedwith anti-caspase-12 and anti-β-actin antibodies, N = 4. (A–C)
These data suggest that calpain and caspase-12 are activated in the P23H RHO retina at P30
and point toward excessive cytosolic Ca2+ content that could perhaps result from persistent
ER stress. (E) Detection of cleaved-9 in P40 transgenic retinas. We analyzed retinal protein
extracts at P40 and found that the level of cleaved-9 was elevated in P23H RHO retina. The
cleavage of caspase-9 was 40% higher in transgenic retina compared to SD (P b 0.05) and
was coincided with the release of cytochrome C and AIF from the P23H RHO mitochondria.
(F) Images of western blots probed with anti-caspase-9 and anti-β-actin antibodies, N = 4.
Fig. 2. Changes in the expression of Bcl2 family proteins in the progressive ADRP retina.
(A) We analyzed retinal protein extracts from SD and P23H RHO rats by two-way
ANOVA and found that the BCL2-XL protein was downregulated at P30 and P40 in P23H
RHO photoreceptors. At P40, we observed a 59% reduction in the amount of BCL2-XL pro-
tein (P b 0.05), N = 4. (B) BAX protein was signiﬁcantly elevated by 1270% (P b 0.0001)
at P30 and by 73% at P30 in the P23H RHO retina, N = 4. (C, D) PUMA andNOXA proteins
had a unique pattern of expression. (C) The PUMA protein was elevated by 73% at P40
(P b 0.01) and (D) NOXA was diminished by 41% at P40 (P b 0.05), N = 4. (E) Images
of western blots probed with ant-Bcl2-xl, BAX, PUMA, NOXA and β-actin antibodies,
N = 4.
Fig. 3.Mitochondria-induced apoptosis in the P23H RHO retina. We separated the retinal
cytosolic andmitochondrial fractions (N = 4) andanalyzed the cytosolic fraction by prob-
ing western blots with antibodies against cytochrome C and cleaved AIF. (A) Using a non-
parametric t-test, we found that at P21 therewas a release of cytochrome C from the P23H
RHOmitochondria to the cytoplasm. The observed density was 140% higher in transgenic
cytosol samples compared to SD (P = 0.02). In addition, we observed a release of cleaved
AIF from P23H RHOmitochondria The observed density for the corresponding band was
290% higher in P23H RHO rats compared to SD, (P = 0.002). At P40, we detected the
translocation of BAX protein into themitochondria of P23H RHO photoreceptors. The den-
sity for the corresponding band was 327% higher in transgenic photoreceptors than in SD
(P = 0.009). The observed time point for this translocation (P40) does not exclude the
possibility that BAX protein translocates to the mitochondria at earlier time points. (B)
Western blot images for blots treatedwith anti-cytochrome C, AIF and BAX antibodies ex-
periment with running anti-β-actin control for the mitochondrial fraction (two last lanes
are positive controls) andCOXIV control for the cytoplasmic fraction (two last gels are pos-
itive controls).
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RHO photoreceptors
We separated themitochondrial fraction of photoreceptor cells from
the cytosol in order to analyze mitochondrial cytochrome C release andthe translocation of AIF into the cytosol (Fig. 3). We found that as early
as P21 there was a greater-than 2-fold accumulation of cytochrome C in
the cytosol of P23H RHO retina photoreceptors (0.053 ± 0.011vs.
0.022 ± 0.005 in SD in a.u., P = 0.02). We also found the release of
the AIF protein from P23H RHO mitochondria. The AIF content of the
P23H cytosol was more than 4-fold higher than in SD (0.25 ± 0.04 in
P23H RHO photoreceptors vs. 0.022 ± 0.02 in SD in a.u., P = 0.002).
The cytochrome C and the AIF1 releases from the mitochondria were
in agreement with elevation of the cleaved caspase-9 by 40%
(0.19 ± 0.01 in P23H RHO photoreceptors vs. 0.12 ± 0.01 in SD in
a.u., P = 0.03) at P40, Fig. 1E, F.
We found that BAX translocated to the mitochondria in P23H RHO
photoreceptors at P40 and that the level of oligomerized BAX protein
in the mitochondria of transgenic rats was 4.7-fold higher than in SD
(0.047 ± 0.008 vs. 0.011 ± 0.005 in a.u., P = 0.009).3.4. Autophagy is modiﬁed in the ADRP retina
The SD and P23H-3 RHO RNA extracts from P13, P21, P30, P40 and
P60 retinas were analyzed to detect expression of the Atg5, Atg7,
Lamp2 and Lc3 autophagy genes (Fig. 4A). The results of this experi-
ment demonstrated that the pattern of autophagy gene expression
was not uniform. For example, in P13 retinas expression of Atg7 and
Atg5 genes was increased by 2.3 ± 0.14 and 1.6 ± 0.29 fold,
(P b 0.0001 and P b 0.5), respectively while expression of the Lamp2
was only 0.43 ± 0.11, P b 0.05 of SD. At P21, expression of Atg5, LC3
and Lamp2 was signiﬁcantly increased and was 3.18 ± 0.22,
Fig. 4. Autophagy gene and protein expression are modiﬁed in P23H-3 RHO photorecep-
tors in a multiphasic manner. (A) Atg5, Atg7, Lamp2 and Lc3 gene expression in P13,
P21, P30, P40 and P60 P23H RHO retinas (N = 4). At P13, expression of Atg5 and Atg7
was upregulated in ADRP photoreceptors by 1.6 and 2.4-fold respectively, while expres-
sion of Lamp2 was downregulated by 2-fold. At P21, expression of all genes, except
Atg7, was upregulated by 3-, 4- and 2.3-fold for Atg5, Lamp2 and Lc3, respectively. At
P30, expression of ATG7 was the only one signiﬁcantly higher compared with controls.
At P40, Atg7, Lamp2 and Lc3 gene expression was signiﬁcantly elevated by 1.6-, 1.9- and
3.0-fold. At P60, expression of all genes was similar to SD with the exception of Atg5,
whichwas downregulated by 2-fold. (B) The level of ATG5, ATG7, LAMP2 and LC3 proteins
was detected in P21, P30, P40 and P60 P23H-3 RHO retinas (N = 4) and the pattern of
protein expression was found to be different from that of mRNA. At P21, no difference in
ATG5, ATG7, LC3 and LAMP2 protein was observed in ADRP photoreceptors. At P30, we
found that ATG5 protein levels were increased by 3.1-fold while levels of ATG7 and
LAMP2 protein were decreased by 40% and by 50%, respectively. At P60, the level of LC3
protein was 60% higher in ADRP photoreceptors vs. SD photoreceptors, which was
signiﬁcant.
Fig. 5. The mTOR/AKT pathway is modiﬁed in the progressive ADRP retina. We analyzed
retinal protein extracts from SD and P23H RHO rats by two-way ANOVA and determined
that mTOR protein expression was signiﬁcantly elevated in the P23H RHO retina at P30
(by 290%; P b 0.05), N = 4. The level of pAKT was reduced at P30 by 75% (P b 0.001)
and at P40 by 44% (P b 0.05), N = 4. Bottom: Images of western blots for P23H-3 RHO
and SD at P30 probed with anti-mTOR, pAKT and β-Actin antibodies.
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spectively compared to SD, however, expression of Atg7 did not differ
signiﬁcantly from SD retinas. At P30, Atg7 and Lc3 gene expression
remained elevated by 1.74 ± 0.19, P b 0.01 and 1.75 ± 0.19, P b 0.01,
respectively while expression of the Lamp2 and Atg5 genes wasdownregulated. At P40 expression of all genes, except Atg5, was signif-
icantly upregulated andwas 1.6 ± 0.15, P b 0.05; 1.90 ± 0.30, P b 0.05
and 3.06 ± 0.27, P b 0.0001 fold higher than SD for Atg7, Lamp2 and
Lc3, respectively. By P60 expression of all genes was diminished, how-
ever only the decrease in Atg5 gene expression was signiﬁcant and
was 0.5 ± 0.13 of SD P b 0.05.
We tested protein extracts from SD and P23H RHO retinas and found
that the changes in the protein level of ATG5, ATG7, LAMP2 and LC3 did
not correlate with alterations in the autophagy gene expression over
the time (Fig. 4B). For example, all proteins with the exception of
ATG5 at P30 and LC3 at P60 were either not signiﬁcantly changed or
signiﬁcantly downregulated compared to SD. ATG5 was elevated by
more than 3-fold (0.28 ± 0.023 in SD vs. 1.01 ± 0.078 in P23H-3
RHO, in a.u., P b 0.0001 at P30) and was downregulated by nearly 2-
fold (0.45 ± 0.029 in SD vs. 0.247 ± 0.040 in P23H-3 RHO a.u.,
P b 0.01) at P60. ATG7 was signiﬁcantly diminished at both the P30
and P60 time points and was 0.45 ± 0.074 in SD vs. 0.22 ± 0.044 in
P23H-3 RHO a.u., P b 0.001 and 0.25 ± 0.015 in SD vs. 0.058 ±
0.0128 a.u. in P23H-3 RHO, P b 0.01, respectively. LAMP2 was also
downregulated at P30 by over 50% and was 1.17 ± 0.17 in SD vs.
0.59 ± 0.093 in P23H-3 RHO a.u., P b 0.05. In contrast, the LC3 protein
showed an increase of 64% at P60 and was 1.88 ± 0.21 in SD vs.
3.03 ± 0.27 in P23H-3 RHO in a.u., P b 0.01.3.5. mTOR/AKT signaling is modiﬁed in progressive P23H
RHO photoreceptors
We analyzedmTOR and phosphorylated AKT (pAKT) in P30 and P40
retinas and found that the level of mTOR protein was elevated in P23H
RHO animals by 290% at P30 (0.029 ± 0.002 vs. 0.01 ± 0.009 in SD
a.u.), P b 0.05 and by 430% at P40 (0.009 ± 0.003 vs. 0.002 ± 0.0003
in SD a.u.) (Fig. 5). In contrast, pAKT protein was signiﬁcantly downreg-
ulated by 75% at P30 (0.013 ± 0.002 in P23H photoreceptors vs.
0.051 ± 0.009 in SD a.u.), P b 0.001 and by 44% at P40 (0.026 ± 0.04
in P23H photoreceptors vs. 0.046 ± 0.005 in SD a.u.), P b 0.05.
Fig. 6. Injectionwith rapamycin slows thedecline of scotopic a-wave ERG amplitude. (A) A
40% increased in a-wave amplitude of scotopic ERGs was observed in P23H-3 RHO rats IP-
injected with rapamycin (RP) (N = 8) vs. vehicle (V)-injected (N = 6) rats, P b 0.05.
There was no difference between a-wave amplitudes in RP-treated animals at 2 and
4 weeks while V-treated rats demonstrated a continued decline in a-wave amplitude.
The B-wave amplitude in rats treated with rapamycin was not changed (not shown).
(B). IP-injected rapamycin led to a decrease in mTOR levels in the P23H-3 RHO retina
after 2 weeks post-treatment. Nearly a 2-fold decrease in the level of mTor was observed
in RP-treated animals, P = 0.012. (C) Images of blots probed with anti-mTor and β-actin
antibodies.(D) Images of the scotopic ERG amplitudes registered at 0 dB or 2.5 cd⁎s/m2 in
RP- and V-treated P23H RHO rats.
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of retinal degeneration
Knowing that rapamycin could modify mTOR signaling, we per-
formed IP injections in P23H-3 RHO rats. Fig. 6 demonstrates results of
the scotopic ERG analysis in RP-treated and V-treated rats. Analysis of
scotopic ERGs revealed that a-wave amplitude was slightly increased
in the RP-treated P23H-3RHO rats at 2 weeks post-treatment
(216 ± 8.8 in V-treated vs. 245 ± 11.98 in RP-treated retinas) and
was increased by 40% in P23H-3RHO rats at 4 weeks post-treatment
compared with controls (176.4 ± 9.4 in V-treated vs. 249 ± 16.5 in
RP-treated), P b 0.05. The b-wave amplitude of the scotopic ERG and
the a- and b-wave amplitudes of the photopic ERG did not change in
the RP-treated P23H-3 RHO rats. Analysis of retinal protein extracts
demonstrated that the mTOR protein was downregulated in RP-
treated animals by nearly 2-fold (0.18 ± 0.02 in RP-treated rats vs.
0.34 ± 0.008 in V-treated animals, P = 0.012.)
4. Discussion
Apoptosis has been shown to be the common pathway of photo-
receptor cell death in several animal models of inherited retinal de-
generation [26]. For example, in rd mice carrying mutant rod cGMPphosphodiesterase, the photoreceptors were found to die by apoptosis.
In S334ter and P23H RHO rats, strong activation of calpain and
poly(ADP-ribose) polymerase (PARP), concomitant with calpastatin
downregulation, increased oxidative DNA damage and accumulation
of PAR polymers was strictly correlated with the temporal progression
of retinal degeneration [27]. We have previously reported UPR activa-
tion in both mutant RHO transgenic rat models. Therefore, because
the UPR might affect general signaling networks in photoreceptor
cells, this study focused on some of the pathways that have been reported
to be tightly controlled by the UPR.
Supporting the hypothesis of a persistent UPR in P23H-3 RHO photo-
receptors, the induction of Ca2+ signaling was observed at P30. The ob-
served activation of calpain and caspase-12 at P30 suggests that Ca2+
release from the persistent UPR may occur. Calpain activity is highly
controlled in vivo by multiple mechanisms, including phosphorylation
by PKA, which negatively regulates calpain activity, and an endogenous
inhibitor, calpastatin [28]. Therefore, the activation of calpain in P23H-3
RHO photoreceptors implies either excessive cytosolic Ca2+ and/or
downregulation of PKA. Neither of these phenomena has thus far been
tested in the P23H RHO retina.
The level of Bcl2 family proteins was also altered during the activated
UPR in P23H-3 RHO retina. For example, the anti-apoptotic BCL2-XL pro-
tein was reduced at P30 and P40, which is indicative of the induction of
transcriptional CHOP during UPR activation, as has been previously
shown inP23H-3RHO retinas [17,19]. ElevatedCHOPmaynegatively reg-
ulate BCL2-XL gene expression [29]. In addition, p53 could be upregulated
and, together with TATA binding protein, negatively control Bcl-2 gene
expression by binding to the Bcl2 promoter TATA sequence [30]. Alterna-
tively, the BAX protein was highly upregulated at P30, which suggests
that the BAX/BCL2-XL ratio is signiﬁcantly increased in transgenic rats.
This in turn could determine the vulnerability of P23H-3 RHO photore-
ceptors to apoptosis that was conﬁrmed in our experiments by detection
of the cleaved caspase-12 and -9. In addition, we found that the BAX
protein translocated to themitochondria at P40 leading toMPTP. The ob-
served time point for translocation (P40) does not exclude the possibility
that BAX translocated at earlier time points. In line with this hypothesis,
we observed the release of cytochrome C and AIF from the mitochondria
to the cytosol of P23H RHO photoreceptors at P21. It is thus possible that
this translocation could occur much earlier.
Other BH3-only proteins such as PUMA and NOXA also demonstrated
altered expression at P30 and P40. Surprisingly, their changes in P23H-3
RHO photoreceptors were distinct. If the PUMA protein was increased at
P40, then NOXA was decreased. Both proteins are well-known p53-
inducible proapoptotic members and could participate in cell signaling
differently [31]. For example, in normal cells, the MPTP induced by
PUMA, but not NOXA, is mediated in part by a Ca2+ release from the ER
[31]. However, upon expression of an oncoprotein such as E1A, induction
of MPTP by NOXA occurs in cells in an ER-independent manner [31]. This
fact provides additional evidence that the ER stress-induced release of
Ca2+ to the cytosol occurs in the P23H RHO retina.
Autophagy has been implicated in various diseases including cancer,
neurodegenerative diseases, pathogen invasion, as well as muscle and
liver disorders. Interestingly, autophagy has been shown to be bothben-
eﬁcial and harmful [32]. In photoreceptor cell death, autophagy partici-
pates in the initiation of apoptosis [33] via a mechanism that in part
depends on the Fas receptor. Autophagy has been shown to occur in
photoreceptors as part of the basal processing of rod outer segments
[34], as well as in animal models of hereditary retinal degeneration
[35]. In our study we found that expression of autophagy-associated
mRNAs was upregulated in the P23H-3 RHO retina and demonstrated
a dynamic expression proﬁle with amajor increase inmRNA expression
at P21. However, the UPR has been previously shown to be activated
at P30 in P23H-3 RHO retina, and thePERK signalingpathway could per-
haps be activated even earlier, leading to an upregulation of autophagy-
related genes [36]. Regardless, by P60 a drop in the expression of
autophagy-related genes was observed. However, the ER stress-
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retinas at P60 as compared to SD [11]. That would suggest that a
cellular mechanism other than the UPR controls autophagy gene
expression in P23H-3 RHO photoreceptors.
Interestingly, protein levels of the corresponding autophagy genes
did not mimic the dynamic alterations seen in the gene expression of
the P23H-3 RHO retina. Recently, it was demonstrated that only 40%
of the variation in protein concentration could be explained by knowing
mRNA levels [37]. The remaining 60% of the variation in protein concen-
tration could be determined by the rates of production and degradation
of the participatingmolecules including the stability of mRNA, the aver-
age half-life of which is ten times less than that of protein. The role of
miRNAs andRNA-binding proteins as potentialmechanisms for regulat-
ing protein abundance was recently highlighted [37] and the inﬂuence
of miRNA deregulation on chaperone-mediated autophagy was also re-
vealed [38]. In the P23H-3RHO retinawe observed a signiﬁcant increase
in autophagy gene expression at P21 that did not result in elevated
levels of autophagy proteins. Moreover, at P30 the downregulation of
LAMP2 and ATG7 proteins was observed. The only exception was
ATG5 that was elevated more than 3-fold compared to controls at P30.
Perhaps, ATG5 translationwas not as affected by posttranslationalmod-
iﬁcations compared to ATG7, LAMP2 and LCA3 proteins whose levels
may have been inhibited by either RNA–protein binding or by protein–
protein interactions. Therefore, the elevated ATG5 protein level at P30 is
a consequence of an increase in its mRNA at P21. For example, it was re-
cently proposed that β-catenin could negatively regulate autophagy by
suppressing formation of the autophagosome and forming the β-
catenin–LC3 complex [39]. Another example is p62 that binds directly
to LC3 leading to degradation of p62- and LC3-positive bodies [40]. This
could happen in addition to awell-known negative regulation of autoph-
agy bymTor, Bcl2, Beclin1 and p53 [41]. In agreementwith these ﬁndings
we found signiﬁcant upregulation of mTOR protein at P30.
mTOR/AKt is known to be a negative regulator of autophagy [42], and
its activity could attenuate autophagy and initiate lysosomal reformation.
Recently, it has been found that during photoreceptor apoptosis in retinal
degeneration in rdmice, the AKT survival pathway is inactivated [43]. In
our ADRP rat model, we also observed downregulation of pAKT, which
suggests that the inactivation of this pathway might have contributed
to photoreceptor cell death. Thus, mTOR is highly upregulated in P30
P23H RHO retinas, which is in agreement with the activation of ATF6
[17]. With respect to the UPR, these data suggest that P30 is a critical
time point for P23H-3 RHO photoreceptors, at which the decision is
made by the cell whether or not to prolong the UPR and to switch from
pro-survival to pro-death UPR signaling. For this reason, we decided to
modulate the mTOR protein using peritoneal injections of rapamycin.
We found that the injections lead to an increase in the scotopic a-wave
ERG response at 4 weeks after treatment. However, this treatment
protected photoreceptors from further functional decline instead of res-
cuing vision in ADRP rats. It also needs to be mentioned that only the
rod photoreceptor cells were sensitive to this treatment and that phot-
opic ERG response, typical for cone photoreceptors was not altered. This
would suggest that the major biochemical imbalance associated with an
increase in mTOR occurs speciﬁcally in rod photoreceptors and that
downregulation of mTOR beneﬁts the ADRP rods expressing P23H RHO.
Surprisingly, we found that inhibition of mTOR in treated retinas did
not lead to an increase in autophagy protein production and that the
ATG5, ATG7, LAMP2 or LC3 proteins were not altered. This fact would
suggest that while downregulation of mTOR is sufﬁcient to protect the
P23H-3 RHO photoreceptors from functional decline to some degree,
proteins other than mTOR are also able to negatively regulate the level
of autophagy in the P23H-3 RHO retina.
5. Conclusions
The current ﬁndings demonstrate that modulation of cellular net-
working occurs in P23H RHO photoreceptors concomitantly with theactivation of the UPR. We demonstrated that during ADRP progression,
mTOR/AKT and autophagy signaling, along with the expression of Bcl2-
family proteins, was altered, and that these alterations coincided with
changes in Ca2+-regulated calpain and caspase-12 activation. In addi-
tion, we found that BAX translocated to the mitochondria and that
this appeared to lead to mitochondria-induced apoptosis during ADRP
progression. These data indicate the potential link between activation
of the UPR and modulation of cellular signaling networks in P23H-3
RHO photoreceptors. However, additional experiments, including the
modulation of UPR signaling by activating or inhibiting individual UPR
arms in P23H-3 RHO retinas are necessary to uncover their relationships
in the progressive ADRP retina. These results also point to a potential
therapeutic target for blocking ADRP progression in P23H-3 RHO rats.
Using mTOR inhibitors such as rapamycin that have been successfully
tested in mice [44–46], and now in rats, could be a promising thera-
peutic approach for treating ADRP.
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